Is This Elon's Worst Nightmare?
Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.
Financials
| Curr Year EPS Estimate | -3.10 |
| Next Quarter EPS Estimate | -0.81 |
| Profit Margin | -4740.03% |
| Operating Margin | -5,488.94 |
| Return on Assets | -0.24 |
| Return on Equity | -0.35 |
| Revenue | 7M |
| Earnings Per Share | -3.84 |
| Revenue Per Share | 0.08 |
| Gross Profit | -335,447,008 |
| Quarterly Revenue Growth | 0.79 |
General
| Name | Ideaya Biosciences Inc |
| Ticker | IDYA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Currency | USD |
| Country | USA |
| Fiscal Year End | December |
| Full Time Employees | 131 |
About Ideaya Biosciences Inc
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Earnings
Silver Nears $50 Amid Inventory Crisis, Outpacing Gold
Silver prices closed last week at multi-year highs, coming within reach of their 2011 peak of $49.95 per ounce.
Woman sues Universal Orlando over injuries from same roller coaster in which man died after ride
ORLANDO, Fla. (AP) — A woman has sued Universal Orlando Resort, claiming she was injured on a roller coaster at its newest theme park. The lawsuit, filed Wednesday, comes a week from blunt impact injuries after going on the same ride.
Why Are Wall Street Insiders Moving Their Money to This One Asset? - Ad
Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.
Cathie Wood Dumps $5.2 Million Worth of This AI Stock, Here's What Ark Bought Instead
Ark Invest decided to sell shares of Tempus AI (TEM), despite positive news of FDA clearance for its diagnostic device. They also made other key trades.
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients
Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients.
Why Trump's "Smart Dollar" Could Rewrite the Rules - Ad
Congress just approved President Trump's latest plans for the dollar - and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.
Donald Trump Declares Harsh Media Coverage of Him 'No Longer Free Speech' But 'Illegal'
President Donald Trump has labeled negative media coverage of him as "illegal."
US bars Iran's diplomats from shopping at Costco without permission
NEW YORK (AP) — The Trump administration has barred Iranian diplomats based in or visiting New York from like Costco and purchasing luxury goods in the United States without specific permission from the State Department.
Nvidia Is About to Shock the World: October 23rd - Ad
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.
Canada's Carney heads to Mexico to discuss trade before a review of their US trade deal
TORONTO (AP) — Canadian Prime Minister Mark Carney heads to Mexico on Thursday in an effort to diversify trade as America’s neighbors brace for a review of the free trade deal with United States.
Day of strikes in France challenges new prime minister's budget plans
PARIS (AP) — Strikes and street demonstrations called by all major trade unions to denounce budget cuts were expected Thursday across France, as new talks with political opponents about curbing .
The "Mar-A-Lago Accord" Is Now Underway - Ad
The global order is in chaos. And according to 40-year market veteran Dr. David Eifrig, the biggest controlled demolition of the old monetary order in history could now be here, too. That means if you don't take action today, your wealth could decline by 40%... (Yes, even your cash savings.)
Bitcoin Soars To Unprecedented Heights, Breaking $125,000 Barrier
Crypto giant Bitcoin (CRYPTO: BTC) has set a new all-time high, surpassing the previous record set in August. The popular cryptocurrency reached a staggering $125,750 in early trading hours on Sunday.
It's 'do or die' for electric vehicle maker Rivian as it breaks ground on a $5 billion plant
ATLANTA (AP) — It seems like a terrible time to build an electric vehicle plant in the United States, but Rivian Automotive leaders say they're confident as the company starts on a $5 billion facility in Georgia.
Time to Say Goodbye to "Old" Dollar? Say Hello to "Trump's New Dollar" - Ad
If you have any money in U.S. dollars... learn how to prepare for "Trump's new dollar"... Because this could be the biggest change to our financial system in 54 years. President Trump even called it: "The greatest revolution in financial technology since the birth of the internet itself."
FedEx Bets On Cost Cuts To Boost Margins, Says Analyst
FDX shares surge on strong quarterly performance, exceeding revenue and profit expectations. Bank of America raises price forecast to $244.
Bitcoin, Ethereum, XRP, Dogecoin Start Monday With Weakness
Cryptocurrency markets are trending down on Monday morning.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
Actor Playing Elon Musk In OpenAI Movie Doesn't Want To Meet Tesla CEO: 'Poisoning My Brain By Watching Lots Of Interviews With Him'
An upcoming 2026 film about OpenAI will see an actor play the role of Elon Musk. Here's how the actor is preparing for playing the billionaire.
Nvidia, Alphabet, Oklo, Webtoon Entertainment And Coreweave: Why These 5 Stocks Are On Investors' Radars Today
Major U.S. indices ended in the green with the Dow Jones Industrial Average rising 0.1% to 45,883.45.
Elon's $25 Trillion Confession - Ad
Elon Musk: "Tesla will become a $25 trillion company." That would make Tesla 8x bigger than Apple today. How is that possible? He admits it's all thanks to this one AI breakthrough that will take AI out of our computer screens and manifest a 250x boom here in the real world.
Many sports fans are unhappy with how much it costs to watch their games, an AP-NORC poll finds
WASHINGTON (AP) — For many dedicated sports fans, keeping up with their favorite teams has become a juggling act.
US To Impose $100,000 Annual Fee On H-1B Visas As Analysts Warn Trump Risks 'Taxing Away' America's Innovation Edge
The Trump administration's plan to impose a $100,000 annual fee on H-1B visas could reshape tech hiring, strain talent pipelines from India and China, and risk driving innovation overseas, analysts warn.
[Revealed] Trump's Next AI Executive Orders? - Ad
A White House insider with direct ties to Trump's inner circle just revealed what he calls "Manhattan II" - a potential $2.2 trillion AI initiative set to launch as soon as Oct 15. He says this could mirror past U.S. projects that minted fortunes - with small firms soaring 5,000% to 10,000% over two decades. And now he's giving away his #1 stock pick for free before the deadline.
FDA takes aim at Hims and other telehealth services in drug advertising blitz
WASHINGTON (AP) — For the first time, federal health officials are taking aim at promoting unofficial versions of prescription drugs — including popular weight loss medications — as part of the on pharmaceutical advertising.
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Is Elon's Empire Crumbling? - Ad
Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after October 23rd, it may be too late.
TikTok Stays Online As Trump Extends US Deadline, Washington Still Demands ByteDance Divestment
President Trump said he and Chinese President Xi Jinping made progress on a TikTok deal and will meet in South Korea in just over a month.
AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.
Is This Elon's Worst Nightmare? - Ad
Elon's empire looks doomed - crashing sales, lost tax credits, and media backlash. But behind the scenes, Tesla is about to unleash a breakthrough Forbes calls a "multi-trillion-dollar opportunity." It's not the end - it's the start of a 25,000% AI comeback.
Natural gas pipeline ruptures in southern Wyoming, setting fire to a freight train
CHEYENNE, Wyoming (AP) — A natural gas pipeline ruptured and burst into flames early Sunday in southern Wyoming, setting fire to a freight train and lighting up the night sky with a glow seen more than 60 miles (nearly 100 kilometers) to the south in Colorado, officials said.
Business News Digest
AP Business Digest
Why Are Wall Street Insiders Moving Their Money to This One Asset? - Ad
Something far more consequential for your money than tariffs is unfolding behind the scenes... Tucked inside this overlooked directive is a plan set to be executed for the first time in in U.S. history. One Stansberry Research's Senior Partner says it's set to trigger a rare window for potentially explosive gains in ONE asset immediately. (Not AI or crypto). Wall Street insiders are already positioning themselves... and he insists you should, too, before it's too late.
Darden, Humana, And Rocket Lab Are Among Top 10 Large Cap Losers Last Week (Sep. 15- Sep. 19): Are The Others In Your Portfolio?
Darden, Humana, Rocket Lab, and FactSet led last week's large-cap losers, with declines driven by weak earnings, guidance, and downgrades.
Nio, Rivian, Moderna, Meta And Bitmine Immersion: Why These 5 Stocks Are On Investors' Radars Today
On Tuesday, U.S. markets slipped, with the Dow Jones Industrial Average falling about 0.3% to 45,757.90, the S&P 500 retreating 0.1% to 6,606.76, and the Nasdaq edging down 0.07% to 22,333.96.These are the top stocks that gained the attention of retail traders and investors throughout the day.
Why Trump's "Smart Dollar" Could Rewrite the Rules - Ad
Congress just approved President Trump's latest plans for the dollar - and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.
Reactions pour in about ABC's suspension of Jimmy Kimmel's show
ABC's following comments he made about the set off a flood of reactions, including from President Donald Trump and a fellow late-night host after he criticized a deal between the Trump administration and his own network's parent company.
Social media has us in its grip and won't let go. The Charlie Kirk killing is a case study
mastery of social media was key to his rise as an influence in conservative politics. So the extent to which and its aftermath have played out on those forums shouldn't come as a surprise.
Nvidia Is About to Shock the World: October 23rd - Ad
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%, is warning everyone to... Mark this date on your calendar: October 23rd! That's when Nvidia could help send shares of this Elon Musk supplier skyrocketing higher.
How To Earn $500 A Month From Steelcase Stock Ahead Of Q2 Earnings
Steelcase offers an annual dividend yield of 2.37% (40 cents a year). How can investors pocket a regular $500 monthly?
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.